閉じてもよろしいですか？
品目がショッピングカートまたはお気に入りに入っていない場合、閉じるとカスタマイズ設定が失われます。
OKをクリックしてMilliplex MAP構成画面を終了するか、キャンセルをクリックして選択画面に戻ってください。
カスタマイズ可能なパネル＆プレミックスキット、またはセルシグナリングMAPmates™を選択する
MILLIPLEX® MAPキットを構成
カスタマイズ可能なパネル＆プレミックスキット
メルクミリポアは豊富な製品ランナップをご用意しています。お客様のニーズに最適なアナライトの組み合わせを選ぶことのできるセレクトキット、あらかじめ複数のアナライトを混合したプレミックスキット、ひとつのアナライトを検出するシングルプレックスからお選びいただけます。
セルシグナリングキット＆MAPmates™
パスウェイやプロセスの探索が可能なプレミックスキットを選択してください。または、シングルプレックスMAPmates™を選択し、ガイドラインに沿ってキットの作製を行ってください。
次のMAPmates™ は一緒に選択しないでください。:
-異なる Assay Buffer が必要なMAPmates™
-リン酸化とTotal MAPmates™の組み合わせ（例: total GSK3βとGSK3β（Ser 9））
- PanTyrと部位特異的MAPmates™ （例: リン酸化EGF受容体とリン酸化STAT1（Tyr701））
- ひとつの標的タンパクに対して複数のリン酸化MAPmate(例：Akt, STAT3)
-GAPDHと β-チューブリンはpanTyrを含むキットもしくはMAPmates™では選択できません。
.
| カタログ番号 | 注文内容 | Qty/Pk | リスト |
この品目はお気に入りに追加されました。
動物種、パネルタイプ、キットまたは試料タイプを選択してください
Milliplex®MAPキットを構するには、動物種およびパネルタイプもしくはキットを選択してください。
| 動物種 |
パネルタイプ |
選択したキット |
サンプルタイプ |
変更 |
| 動物種を選択 | . |
| パネルタイプを選択 | . |
| キットを選択 | . |
| サンプルタイプを選択 | 一緒に測定するアナライトを決定する同じ種類のパネルもあります。 |
マルチプレックスパネルからアナライトを選択するか、プレミックスおよびシングルプレックスキットから選択してください
ご自身でキットをカスタマイズするか、シングルプレックスおよびプレミックスパネルから選択してください。
Custom Premix
Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
| Catalogue Number | Ordering Description | Qty/Pack | List |
この品目はお気に入りに追加されました。
| 動物種 |
|
| パネルタイプ | |
| 選択したキット | |
| 数量 | カタログ番号 | 注文内容 | Qty/Pk | 価格 |
| 96-Well Plate |
| 数量 | カタログ番号 | 注文内容 | Qty/Pk | 価格 |
その他の試薬を追加 （MAPmatesとともに使用するにはバッファーおよび検出キットが必要です）
| 数量 | カタログ番号 | 注文内容 | Qty/Pk | 価格 |
| 48-602MAG | Buffer Detection Kit for Magnetic Beads | 1 Kit |
Space Saver Option（チェックを入れると箱詰めから袋詰めに変更となりますのでご注意ください）
Customers purchasing multiple kits may choose to save storage space by eliminating the kit packaging and receiving their multiplex assay components in plastic bags for more compact storage.
Customers purchasing multiple kits may choose to save storage space by eliminating the kit packaging and receiving their multiplex assay components in plastic bags for more compact storage.
この品目はお気に入りに追加されました。
製品がカートに追加されました
別のキットをカスタマイズしたり、プレミックスキットを選択したり、注文ツールを確認したり閉じたりできるようになりました。
Pharma and Biopharma Manufacturing Webinars
Browse Our On-Demand Webinars:
Register Today for Our Upcoming Webinars
Take part in our complimentary, live webinars, where you’ll interact with experts who are breaking ground in the pharmaceutical and biopharmaceautical industries. You’ll learn about the newest tools and technologies while gathering valuable tips and troubleshooting strategies for the applications most relevant to your processes.
Find an upcoming webinar below and register today!
Reducing Risk and Decreasing Timelines for Biopharmaceutical Cell Line Development Through Optimized Reagents and Processes
|
Abstract: Join us to learn about challenges faced with traditional expression systems and how a CHO cell line with the glutamine synthetase knock-out via ZFN provides benefits for fast, efficient cell line development with stable and high titer expression. CHO cells with their unique characteristics, represent the major expression system within the biopharmaceutical industry. However, one of the major challenges in cell line development is to identify those rare, high-producing clones in a huge population of non-expressing or low-expressing cell lines. This leads to laborious and time consuming cell line development processes. This webinar will educate the audience about challenges faced with traditional expression systems and how the CHO cell line with the glutamine synthetase knock-out via Zinc Finger Nucleases provides benefits for fast and efficient cell line development as well as stable and high titer expression. We will explore additional cell line engineering targets that can be modified to engineer a cell line that mitigates risks and removes bottlenecks throughout the biopharmaceutical process. In this webinar, you will learn:
|
A Molecule’s Journey – Breaking Down Roadblocks to Commercial Success
|
Abstract: Every biopharma executive must make important decisions early in clinical development that will impact their molecule’s journey – and ultimately the success of their commercial strategy. The key to this success is to make the right decisions at the right time. In this webinar, our experts share some key considerations to help biopharmaceutical companies successfully advance a molecule from the laboratory to the clinic as quickly as possible without sacrificing product quality, process efficiency, or patient safety. To achieve this goal, companies must navigate the complexities associated with business planning, cell line development, process development, technology, and regulatory and risk assessment. In this webinar, you will learn:
|
Comprehensive Assessment of a Stimulus-Responsive Flocculation Polymer for Cell Culture Clarification
|
Abstract: This webinar will provide a comprehensive, holistic assessment of the effects of Clarisolve® mPAA flocculation polymer pre-treatment upon clarification and subsequent downstream chromatography steps. Flocculation is a simple method to pre-clarify high density Chinese hamster ovary (CHO) cell culture feed streams, allowing for an efficient clarification process that would otherwise not be feasible using traditional depth filters. Clarisolve® mPAA polymer is a stimulus-responsive flocculation polymer that may provide a reduced dosing dependency and lower residual polymer levels when compared to other flocculants. Cell culture pre-treatment with Clarisolve® mPAA polymer followed by clarification using Clarisolve® 60HX depth filters, enables a significant increase of harvest throughputs and allows for a single clarification stage for these high-density feed streams. Furthermore, by eliminating the need for centrifugation, pre-treatment with Clarisolve® mPAA polymer allows for the implementation of a single-use clarification train.This webinar will review the efficacy of pretreatment with a range of Clarisolve® mPAA polymer concentrations upon the clarification and purification of a CHO cell culture feed stream. These results were compared to material prepared using conventional Millistak+® HC depth filtration media to deliver a comprehensive, holistic assessment of the effects of Clarisolve® mPAA polymer pre-treatment upon the clarification and subsequent downstream chromatography steps. In this webinar, you will learn more about:
|
Overview of the Regulatory Landscape for Plastic Devices in Pharmaceutical Manufacturing
|
Abstract: This webinar highlights regulations for plastic devices in pharmaceutical manufacturing, a risk-based approach to qualifying components, and the importance of regulatory documentation. The growing complexity of therapeutics and globalization are some of the factors leading to innovative manufacturing solutions. Thanks to their flexibility and ease of use, polymeric materials are being used more frequently in the manufacturing of pharmaceuticals and biopharmaceuticals. Consequently, the development and qualification of plastic components requires a purposeful implementation of a multifaceted regulatory guidance. However, the lack of regulations specific to plastics used in pharmaceutical manufacturing systems has led to considerable uncertainty. In this webinar, you will learn:
|
Identifying Appropriate-Quality Pharmaceutical Raw Materials in an Evolving Regulatory Environment
Session 1: 3:00 AM EST, 12 AM PST, 9 AM CET View your Time Zone start time
Register Now Session 2: 11:00 AM EST, 8 AM PST, 5 PM CET View your Time Zone start time
Register Now |
Abstract: This webinar will discuss appropriate quality attributes for different raw material uses, present strategies to support identification, selection and risk assessment of raw materials, and highlight the importance of regulatory documentation. Recent and continuing regulatory improvements require drug manufacturers to assess and mitigate risk throughout their entire processes. This includes raw materials used at every stage of manufacturing and clinical phases. Current regulatory guidelines and industry standards clearly define quality requirements for raw materials that are incorporated into, or used close to, final drug product, for example active ingredients and excipients. However, no such clear standards are defined for chemicals used earlier in the process, such as in upstream bioprocessing, early chemical synthesis stages, or clean-in-place. The absence of such standards presents a challenge to efficiently and effectively source raw materials with appropriate supply chain transparency and control, accompanied by the necessary supporting documentation. In this webinar, you will learn:
|